|
| Status |
Public on Jul 14, 2015 |
| Title |
1_H526-DMSO_LSD1 |
| Sample type |
SRA |
| |
|
| Source name |
NCI-H526 small cell lung cancer cell line
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: NCI-H526
cell type: epithelial
passages: multiple
chip antibody: LSD1
|
| Treatment protocol |
1 uM GSK2879552 for 24 hours
|
| Growth protocol |
RPMI/10%FBS
|
| Extracted molecule |
genomic DNA |
| Extraction protocol |
SDS buffer after crosslinking
|
| |
|
| Library strategy |
ChIP-Seq |
| Library source |
genomic |
| Library selection |
ChIP |
| Instrument model |
Illumina HiSeq 2000 |
| |
|
| Description |
LSD1 ChIP-seq in DMSO treated H526 cells
|
| Data processing |
Sequence reads were aligned to the reference human genome (hg19) using BWA with default parameters
We filtered out reads mapping to multiple locations and removed PCR duplicates using Picard MarkDuplicates
Enriched ChIP-seq regions were identified using MACS 2.0 (q-value < .01)
Read density tracks were calculated using in-house programs and visualized using the UCSC and IGV genome browsers
Genome_build: hg19
Supplementary_files_format_and_content: BED - enriched ChIP-seq regions; Definition of columns are: 5th: integer score for display, 7th: fold-change, 8th: -log10pvalue, 9th: -log10qvalue
Supplementary_files_format_and_content: bigWig - genome browser track - tag density
|
| |
|
| Submission date |
Feb 25, 2015 |
| Last update date |
May 15, 2019 |
| Contact name |
David Soong |
| Organization name |
GlaxoSmithKline
|
| Street address |
1250 S Collegeville Rd
|
| City |
Collegeville |
| State/province |
PA |
| ZIP/Postal code |
19426 |
| Country |
USA |
| |
|
| Platform ID |
GPL11154 |
| Series (2) |
| GSE66297 |
A DNA Hypomethylation Signature Predicts Novel Anti-Tumor Activity of LSD1 Inhibitors in SCLC (ChIP-Seq) |
| GSE66298 |
A DNA Hypomethylation Signature Predicts Novel Anti-Tumor Activity of LSD1 Inhibitors in SCLC |
|
| Relations |
| BioSample |
SAMN03375123 |
| SRA |
SRX890395 |
